Agenus Secures $85M Upfront, Up to $340M PIPE to Fund Pivotal Colon Cancer Trial

summarizeSummary

Agenus announced an $85M upfront private placement, potentially worth up to $340M, to fund its pivotal Phase 3 ROBBIN trial of neoadjuvant BOT+BAL in MSS colon cancer. The financing extends the cash runway through key data readouts and supports a strategic pivot away from the metastatic BATTMAN study.

check_boxKey Events · Financing and Capital Events · AGEN

• $85M Upfront PIPE, Up to $340M Total

  Agenus entered a securities purchase agreement for a private placement of 23,035,227 shares (or pre-funded warrants) at $3.69 per unit, raising $85M upfront. Accompanying Series A and B warrants for 21.1M and 33.8M shares, with exercise prices of $4.02 and $5.03 respectively, could bring total proceeds to $340M.

• Funding Pivotal ROBBIN Phase 3 Trial

  Proceeds are earmarked for the registrational ROBBIN trial of neoadjuvant BOT+BAL in high-risk Stage II/III MSS colon cancer. This 850-patient randomized study uses event-free survival as the primary endpoint, is FDA-aligned, and expects first patient dosing in Q1 2027, with interim pathologic response data in H2 2027.

• Strategic Pivot and Pipeline Prioritization

  To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the BATTMAN Phase 3 trial in late-line metastatic MSS CRC. In Phase 2 studies, BOT+BAL has demonstrated 30% pathologic complete responses and no recurrences.

• Cash Runway Extended Through Key Catalysts

  With the upfront proceeds, Agenus expects cash to fund operations into Q3 2027. Full warrant exercise would extend the runway through year-end 2031, covering the ROBBIN trial's interim and final EFS analyses.

auto_awesomeAnalysis · AGEN · Life Sciences

A transformative private placement led by Commodore Capital, RA Capital, and others delivers $85 million upfront to Agenus, with the potential to reach $340 million if all warrants are exercised. The capital is earmarked for the registrational ROBBIN Phase 3 trial of neoadjuvant BOT+BAL in MSS colon cancer—a U.S. market exceeding $7 billion that has seen no new therapies in over 20 years. By extending the cash runway to Q3 2027 under the base case, or through year-end 2031 upon full warrant exercise, the financing de-risks the company through key data readouts. As part of a strategic pivot, Agenus is discontinuing the BATTMAN metastatic trial to concentrate resources on the curative-intent neoadjuvant setting, where BOT+BAL has already demonstrated 30% pathologic complete responses and no recurrences in Phase 2. The deal includes board seats for Commodore Capital and warrants priced at premiums to market, signaling strong institutional confidence. Existing shareholders face significant dilution—up to 78 million new shares if all warrants are exercised—but the capital removes the near-term financing overhang and aligns funding with major catalysts.